Highlights of the Pananemia National meeting of the Italian Southern Oncological Group (GOIM): Pharmacological and molecular treatment of cancer-induced anemia - Sorrento, Italy, 19 - 20 December 2008

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 6, 2009, Pages 1089-1093

  Addeo, Raffaele ^b   Caraglia, Michele ^a   Del Prete, Salvatore ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b SAN GIOVANNI DI DIO HOSPITAL   (Italy)

Author keywords

Cancer related anemia; Erythropoietin beta; Iron; Non erythropoietin ESAs; Prolyl hydroxylase inhibitors; Quality of life

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERRITIN; HEMOGLOBIN; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADJUVANT CHEMOTHERAPY; ANEMIA; CANCER CELL; CANCER PATIENT; CANCER SURGERY; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FATIGUE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; MOLECULAR MECHANICS; OVERALL SURVIVAL; PATIENT SATISFACTION; PRACTICE GUIDELINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TRANSFERRIN BLOOD LEVEL; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANEMIA; ANIMALS; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; ITALY; MEDICAL ONCOLOGY; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67649622153     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902868159     Document Type: Conference Paper

References (14)

1. Bunn HF. New agents that stimulate erythropoiesis. Blood 2007;109:868-873 •• This manuscript describes the signal transduction pathway induced by erytrhopoietin (Epo) and all the new erythropoiesis-stimulating agents (ESAs), including also the non-erythropoietin ESAs. (Pubitemid 46220629)
2. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008;141:14-31 • The review describes the effects of Epo on organs different from bone marrow disclosing new indications for Epo and ESAs generally. (Pubitemid 351347536)
3. Leyland-jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-5972 •• This trial is the first describing negative effects induced by Epo administration on overall survival of cancer patients affected by breast cancer. The authors found a higher incidence of disease progression in the arm treated with Epo alpha, and the increase of the death-related events was independent from thromboembolic events. (Pubitemid 46300213)
4. Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005;23:6941-6948 (Pubitemid 46260280)
5. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia anagement with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl):33-6 • In this manuscript the last guide lines of EORTC regarding the use of Epo are described.
6. Auerbach M. Should intravenous iron be the standard of care in oncology? J Clin Oncol 2008;26:1579-1581
7. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoietin alfa. J Clin Oncol 2008;25:1619-1625 • This trial demonstrates the importance of an adequate supplementation with i.v. iron (not oral) in the correction of anemia in patients treated with darbepoietin.
8. Bastit L, Vandebroek A, Altintas S, et al. A randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoietin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;25:1611-1618
9. Coyne D. Iron indices: what do they really mean? Kidney Int Suppl 2006;101:S4-8
10. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology 2005;69(Suppl):2-7 (Pubitemid 41507248)
11. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;19:3407
12. Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 2006;106:223-233 (Pubitemid 43032569)
13. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260 •• This is the second study demonstrating a negative impact of Epo on cancer patient survival. (Pubitemid 37324251)
14. Pronzato P, Jassem J, Mayordomo J. Epoetin beta therapy in patients with solid tumours. Crit Rev Oncol Hematol 2006;58:46-52